Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease

Table 1 Description of study participants n (%)

	CD (n = 327)	UC (n = 495)	Controls (n = 779)
Sex
Male	129 (39)	239 (48)	400 (51)
Female	198 (61)	256 (51)	379 (49)
Age (yr)
Median (5%-95%)	43 (23-76)	49 (24-76)	43 (23-60)
Age at diagnosis (yr)
Median (5%-95%)	30 (15-64)	35 (17-68)
Smoking habits
Smokers	167 (51)	86 (17)	205 (26)
Never smokers	115 (35)	226 (46)	391 (50)
Former smokers	45 (14)	183 (37)	183 (23)
Location of UC
Proctitis (E1)		207 (42)
Left side (E2)		183 (37)
Extensive (E3)		93 (19)
Data not available		12 (2)
Location of CD
Colonic (L2)	151 (46)
Ileal (L1)	74 (23)
Ileocolonic (L3)	89 (27)
Data not available	13 (4)
Medication
Advanced1	140 (43)	103 (21)
No advanced medication2	182 (56)	389 (79)
Data not available	5 (2)	3 (1)
Operation
Yes	149 (46)	14 (3)
No	171 (52)	472 (95)
Data not available	7 (2)	9 (2)

Disease location was classified according to the WGO Montreal classification. Statistical analyses included subjects for whom all information was available.

¹Azathioprine, 6-mercaptopurine, tumor necrosis factor inhibitors, or methrotrexate;

²5-aminosalicylic acid, prednisolone. CD: Crohn’s disease; UC: Ulcerative colitis.